PNC-27 Reference

Plain English

What it is

PNC-27 is an experimental peptide (a short chain of protein building blocks) that scientists have studied in the lab for its effect on cancer cells. It is not an approved medicine. So far it has only been looked at in cells and animals, not in people.

What people use it for

It gets talked about in fringe cancer circles because lab studies suggest it can grab onto a protein on the surface of cancer cells and break those cells apart while leaving normal cells alone. This is laboratory research being indexed for education, not a tested treatment or any kind of health guidance.

What the science shows

In test tubes and cell studies, PNC-27 binds a protein called HDM-2 sitting on the outer membrane of cancer cells, opens holes in those cells, and damages their internal energy parts (mitochondria), which makes the cancer cells die. These studies report it kills cancer cells but not normal cells. None of this has been shown in humans, because it has never been tested in a human cancer trial.

The catch

This is an experimental anticancer compound with only laboratory and animal data and no human trials, so there is no proof it treats any cancer in people. It is not FDA-approved, and using it instead of real cancer care would be medically dangerous. Treat it as a laboratory research compound only, not a cancer treatment.

Reference summary

In-vitro and mechanistic studies describe cancer-cell membrane HDM-2 binding, pore formation, and mitochondrial disruption. Human clinical efficacy data are absent.

Regulatory and posture

Categories

Immune

Aliases

p53-derived HDM-2-binding peptide, PNC27, Anticancer research peptide

Evidence posture

preclinical - Fringe anticancer peptide. No human clinical efficacy evidence; using it instead of oncology care would be medically dangerous. This entry is educational source indexing only.

Regulatory status

No FDA-approved PNC-27 drug label. PNC-27 is not an approved cancer treatment. Published work is mostly cell, mechanistic, and preclinical oncology research.

Content review status

research reference